Syncom Formulations board meet 2026: Q1 results, dividend

What the latest corporate update is about

Syncom Formulations (India) Limited has scheduled a board meeting for Tuesday, August 11, 2026, where directors will consider the company’s quarterly financial results and a possible final dividend recommendation. The meeting also coincides with a key management change, with the company’s founder stepping down from board and executive roles effective the same day. Together, these developments bring financial disclosure and governance into focus for investors tracking the company’s near-term direction.

The disclosures are part of regular compliance under SEBI (LODR) requirements, with the company intimating the stock exchange about the agenda and timing. The updates also follow earlier board meetings held through FY26 for quarterly and annual results.

Share price snapshot around the announcement

As per the information provided, SYNCOMF was at ₹14.53 on August 11, 2026. The data also shows a BSE price of ₹14.46 as of 10 August at 04:01 PM, reflecting a rise of 7.59% on the day. Another reference point cited is ₹13 as of 8 August, 2026.

These are point-in-time prices from different timestamps in the provided material, and they indicate elevated short-term movement around the period of corporate announcements. The same dataset also mentions “1 Year Returns: -25.25%”, indicating the stock’s longer period performance as stated in the source.

Board meeting on August 11, 2026: timing and venue

Syncom Formulations informed BSE that its 2/2026-27 meeting of the Board of Directors is scheduled for August 11, 2026 at 4:00 PM IST. The venue stated is the corporate office at 207, Saket Nagar, Near Saket Club, Indore (M.P.) 452018.

The exchange intimation notes that the meeting is being held under Regulation 29(1)(a) of SEBI (LODR) Regulations, 2015 read with SEBI (PIT) Regulations, 2015. Such intimations typically cover the date, time, and items to be considered so that market participants have equal access to material information.

Agenda: Q1 FY27 unaudited results and limited review report

The board is scheduled to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. Alongside the results, the board will take on record the limited review report by the auditors.

This is the standard format for quarterly reporting for listed entities. The mention of both standalone and consolidated numbers indicates the company intends to publish the results at both entity and group levels, as applicable.

Agenda: FY26 final dividend recommendation

The August 11, 2026 board meeting agenda also includes consideration of a final dividend recommendation for the financial year ended March 31, 2026. The material provided does not specify the dividend amount or payout ratio, only that the recommendation will be considered.

Any final dividend, if recommended by the board, typically moves through the required shareholder approval process depending on applicable rules and the company’s governance framework. Investors generally watch for the declared amount, record date, and payment timelines in the eventual disclosures.

Founder Kedarmal Shankarlal Bankda resigns effective August 11, 2026

Separately, Syncom Formulations has accepted the resignation of its founder, Kedarmal Shankarlal Bankda, from the offices of Whole-Time Director and Director, effective August 11, 2026. The information provided states the resignation is voluntary, citing health and succession planning, and that it follows a five-decade tenure with no disagreements.

The cessation of his roles is stated to take effect at the close of business hours on August 11, 2026. The company’s board acknowledged his contributions and confirmed the transition, as per the provided text.

Earlier board meetings referenced in the disclosures

The provided material also references other board meetings across FY26 and earlier. Syncom Formulations held a board meeting on February 12, 2026 at 3:00 PM to consider and approve standalone and consolidated unaudited financial results for Q3 FY26 and nine months ended December 31, 2025, along with auditors’ limited review reports.

Another board meeting is cited for May 22, 2026 at 3:00 PM at the Indore corporate office to consider standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The data further notes that the company’s board had previously approved the financial statements during this May 22, 2026 meeting.

A separate line also mentions: “Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company on 12 November 2025.” The provided text does not add the agenda for that 2025 meeting.

FY26 audited results and auditor opinion mentioned in the material

The source includes FY26 audited financial highlights stating revenue from operations of ₹48.657 crore and profit of ₹7.601 crore for the year ended March 31, 2026 (converted from ₹486.57 million and ₹76.01 million). It also states that the auditors’ report on the financial results is unmodified, and that the results will be published in English and Marathi newspapers and filed in XBRL format.

Separately, the material states: “The company reported a 55.5% increase in consolidated net profit to ₹764.38 crore for FY26, while Q4 net profit rose to ₹25.17 crore.” These figures are presented as consolidated profit numbers in the provided content, and they are not reconciled in the text with the standalone audited highlights above.

SEBI disclosure note on “Large Corporate” classification

The provided information also says Syncom Formulations (India) Limited confirmed to BSE and NSE on April 3, 2026, that it does not qualify as a “Large Corporate” under SEBI regulations. This classification typically relates to certain disclosure and fundraising norms, and the statement is relevant for compliance tracking.

Key facts table: dates, agenda items, and stated numbers

Market relevance: what investors will track next

The most immediate market-moving items from the August 11 agenda are the Q1 FY27 unaudited results and the final dividend recommendation for FY26. Financial statements and the accompanying limited review report typically provide updated signals on operating performance, margins, and cash flows. Dividend recommendations, meanwhile, tend to influence near-term sentiment, particularly for investors focused on payouts.

The founder’s resignation effective the same day adds an additional governance lens. While the source states the exit is voluntary and without disagreements, investors usually watch subsequent filings for any changes in board composition, executive responsibilities, or succession structure.

Conclusion

Syncom Formulations’ August 11, 2026 board meeting brings together quarterly reporting for the period ended June 30, 2026 and a possible FY26 final dividend recommendation, alongside the founder’s exit from board and executive roles effective that day. The next concrete milestones are the board’s outcome disclosures after the meeting, including the published standalone and consolidated results, the auditors’ limited review report, and any dividend recommendation details.